Sunflower Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sunflower Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Jinling Pharmaceutical Company Limited
sales of 3.58 billion Chinese Renmimbi [US$555.75 million]
of which 73%
was Medicine Manufacture),
Renhe Pharmacy Company Limited
(3.57 billion Chinese Renmimbi [US$554.12 million]
of which 99%
was Medicine), and
Sihuan Pharmaceutical Holdings Group Ltd
(3.19 billion Chinese Renmimbi [US$494.90 million]
of which 100%
was Pharmaceutical Prods).
Sunflower Pharmaceutical Group Co Ltd reported sales of 3.36 billion Chinese Renmimbi (US$522.07 million)
December of 2016.
increase of 10.8%
versus 2015, when the company's sales were 3.03 billion Chinese Renmimbi.
Sales at Sunflower Pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 116%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
282.2% in 2016, from
19.37 million Chinese Renmimbi to 74.04 million Chinese Renmimbi.
Not all segments of Sunflower Pharmaceutical Group Co Ltd experienced an increase in sales in 2016:
sales of Headquarter fell 3.6% to 6.89 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).